News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
7,713 Results
Type
Article (1882)
Company Profile (3)
Press Release (5828)
Multimedia
Podcasts (11)
Webinars (1)
Section
Business (3190)
Career Advice (22)
Deals (439)
Drug Delivery (4)
Drug Development (1712)
Employer Resources (12)
FDA (213)
Job Trends (312)
News (5010)
Policy (429)
Tag
Academia (42)
Accelerated approval (2)
Adcomms (2)
Alliances (644)
ALS (11)
Alzheimer's disease (317)
Antibody-drug conjugate (ADC) (1)
Approvals (204)
Artificial intelligence (1)
Autoimmune disease (2)
Bankruptcy (4)
Best Places to Work (165)
Biosimilars (8)
Biotechnology (2)
Breast cancer (2)
Cancer (10)
Cardiovascular disease (6)
Career advice (23)
Career pathing (1)
Cell therapy (4)
Clinical research (1178)
Collaboration (13)
COVID-19 (44)
CRISPR (1)
C-suite (7)
Cystic fibrosis (1)
Data (17)
Depression (6)
Diabetes (1)
Diagnostics (40)
Diversity, equity & inclusion (4)
Drug discovery (5)
Drug pricing (2)
Drug shortages (1)
Duchenne muscular dystrophy (8)
Earnings (739)
Editorial (6)
Employer branding (8)
Employer resources (12)
Events (845)
Executive appointments (32)
FDA (227)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (9)
Gene editing (2)
Gene therapy (2)
GLP-1 (38)
Government (66)
Guidances (2)
Healthcare (113)
Huntington's disease (4)
IgA nephropathy (5)
Immunology and inflammation (10)
Indications (1)
Infectious disease (45)
Inflammatory bowel disease (2)
Inflation Reduction Act (1)
Interviews (1)
IPO (131)
Job creations (144)
Job search strategy (23)
Labor market (1)
Layoffs (30)
Legal (89)
Lung cancer (3)
Lymphoma (2)
Management (1)
Manufacturing (3)
Medical device (20)
Medtech (20)
Mergers & acquisitions (311)
Metabolic disorders (12)
Multiple sclerosis (6)
Neurodegenerative disease (21)
Neuropsychiatric disorders (5)
Neuroscience (355)
NextGen: Class of 2025 (125)
Non-profit (40)
Northern California (21)
Obesity (12)
Opinion (31)
Pain (2)
Parkinson's disease (4)
Partnered (1)
Patents (3)
People (1548)
Pharmaceutical (1)
Phase I (305)
Phase II (490)
Phase III (597)
Pipeline (11)
Policy (4)
Postmarket research (78)
Preclinical (91)
Prostate cancer (1)
Psychedelics (1)
Rare diseases (16)
Real estate (90)
Recruiting (3)
Regulatory (332)
Research institute (31)
RSV (1)
Schizophrenia (4)
Series A (2)
Series B (2)
Sickle cell disease (1)
Southern California (6)
Special edition (3)
Spinal muscular atrophy (67)
Startups (107)
The Weekly (11)
United States (184)
Vaccines (6)
Weight loss (7)
Women's health (1)
Date
Today (1)
Last 7 days (7)
Last 30 days (24)
Last 365 days (395)
2025 (124)
2024 (405)
2023 (455)
2022 (670)
2021 (685)
2020 (584)
2019 (474)
2018 (396)
2017 (533)
2016 (549)
2015 (672)
2014 (340)
2013 (262)
2012 (202)
2011 (197)
2010 (182)
Location
Africa (32)
Asia (596)
Australia (52)
California (40)
Canada (16)
China (11)
Colorado (1)
Connecticut (4)
Europe (1127)
Florida (3)
Illinois (2)
India (1)
Indiana (1)
Japan (10)
Maine (1)
Maryland (3)
Massachusetts (88)
Missouri (1)
Nevada (1)
New Hampshire (2)
New Jersey (7)
New York (18)
North Carolina (5)
Northern California (21)
Ohio (1)
Oregon (1)
Pennsylvania (3)
Rhode Island (1)
South America (34)
Southern California (6)
Texas (4)
Virginia (1)
Washington State (12)
Wisconsin (1)
7,713 Results for "biogenes".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
January 27, 2025
·
1 min read
·
Annalee Armstrong
Legal
Sage Sues Partner Biogen After Unsolicited Takeover Offer
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital Markets.
January 21, 2025
·
2 min read
·
Tristan Manalac
Neuroscience
Biogen Submits Offer to Buy Embattled Partner Sage
Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of Sage Therapeutics have fallen by more than 90%.
January 13, 2025
·
3 min read
·
Heather McKenzie
Accelerated approval
Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs
An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, Sarepta’s Exondys and Covis’ Makena.
January 15, 2025
·
2 min read
·
Tristan Manalac
Podcast
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More
Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees more action with new company launches, IPOs and fresh data; and experts get ready for an important era in the Duchenne muscular dystrophy space.
January 29, 2025
·
1 min read
·
Heather McKenzie
Business
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference. Meanwhile, Biogen proposes to acquire struggling neuro partner Sage, and obesity dominates discussions as Pfizer goes “all in.”
January 15, 2025
·
1 min read
·
Heather McKenzie
Collaboration
Biogen Taps Royalty Pharma for $250M to Power Phase III Lupus Program
The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the company’s forecasted dip in 2025 revenues.
February 12, 2025
·
2 min read
·
Tristan Manalac
Business
Under Pressure to Deal, Biogen Executives Deflect Urgency at JPM25
While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to make one out of desperation.
January 15, 2025
·
3 min read
·
Annalee Armstrong
Earnings
With Leqembi Sales Trending Up, Biogen Gets Down to Brass Tacks: It Works
Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s disease. With patients now hitting the 18-month mark of treatment, the conversation is finally shifting to efficacy.
February 12, 2025
·
3 min read
·
Annalee Armstrong
Business
5 Reasons Biogen’s Shares Have Dropped 36% in 2024
A slow launch for Alzheimer’s medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a few of the factors that have sent Biogen’s shares down this year.
November 13, 2024
·
7 min read
·
Annalee Armstrong
1 of 772
Next
